ARWR - Arrowhead Pharmaceuticals Inc Stock Price, Fair Value and News

24.77USD-0.23 (-0.92%)Delayed

Market Summary

USD24.77-0.23

Delayed

-0.92%

ARWR Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

ARWR Stock Price

View Fullscreen

ARWR RSI Chart

ARWR Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-6.53

Price/Sales (Trailing)

12.77

EV/EBITDA

-6.71

Price/Free Cashflow

-6.54

ARWR Price/Sales (Trailing)

ARWR Profitability

EBT Margin

-198.58%

Return on Equity

-95.03%

Return on Assets

-49.29%

Free Cashflow Yield

-15.28%

ARWR Fundamentals

ARWR Revenue

Revenue (TTM)

240.7M

Rev. Growth (Yr)

-49.02%

Rev. Growth (Qtr)

1.72%

ARWR Earnings

Earnings (TTM)

-470.8M

Earnings Growth (Yr)

-357.42%

Earnings Growth (Qtr)

5.69%

Breaking Down ARWR Revenue

Last 7 days

12.2%

Last 30 days

9.9%

Last 90 days

-16.0%

Trailing 12 Months

-31.7%

How does ARWR drawdown profile look like?

ARWR Financial Health

Current Ratio

8.31

ARWR Investor Care

Shares Dilution (1Y)

16.18%

Diluted EPS (TTM)

-4.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	272.8M	256.2M	240.7M	0
2022	263.4M	249.9M	243.2M	278.3M
2021	89.1M	107.6M	138.3M	144.4M
2020	139.0M	123.7M	88.0M	79.8M
2019	94.8M	136.8M	168.8M	163.6M
2018	22.2M	13.6M	16.1M	47.3M
2017	18.9M	25.2M	31.4M	30.6M
2016	255.0K	170.8K	6.4M	12.7M
2015	302.0K	382.0K	382.0K	255.0K
2014	175.0K	175.0K	175.0K	302.0K
2013	294.4K	290.3K	290.3K	175.0K
2012	55.2K	103.1K	146.9K	281.9K
2011	0	0	296.1K	24.0K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Arrowhead Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	vakiener victoria	sold	-41,934	23.31	-1,799	-
Apr 01, 2024	hamilton james c	sold	-168,180	28.03	-6,000	chief discovery/trans medicine
Mar 20, 2024	lu hongbo	bought	27,500	27.5	1,000	-
Mar 19, 2024	lu hongbo	bought	28,000	28.00	1,000	-
Mar 18, 2024	lu hongbo	bought	27,490	27.49	1,000	-
Mar 06, 2024	myszkowski kenneth allen	sold	-1,407,600	35.19	-40,000	chief financial officer
Jan 31, 2024	anzalone christopher richard	acquired	836,035	14.54	57,499	chief executive officer
Jan 31, 2024	anzalone christopher richard	sold	-1,860,020	32.3487	-57,499	chief executive officer
Jan 12, 2024	hamilton james c	sold	-292,904	36.8896	-7,940	chief discovery/trans medicine
Jan 11, 2024	waddill william d.	sold	-149,759	38.0678	-3,934	-

Which funds bought or sold ARWR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	added	11.17	51,939	1,381,720	0.01%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	14.1	218,190	3,503,100	-%
May 16, 2024	Clear Point Advisors Inc.	unchanged	-	-3,706	52,996	0.04%
May 16, 2024	JANE STREET GROUP, LLC	added	54.25	1,122,110	3,662,860	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	28.57	159,836	952,437	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	9,351,370	9,351,370	-%
May 15, 2024	HOYLECOHEN, LLC	unchanged	-	-31,100	444,730	0.03%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-74.74	-322,424	99,642	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	363,220	363,220	0.02%
May 15, 2024	EVENTIDE ASSET MANAGEMENT, LLC	unchanged	-	-626,578	8,960,060	0.14%

Are Funds Buying or Selling ARWR?

Are funds buying ARWR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARWR

No. of Funds

Unveiling Arrowhead Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	vanguard group inc	10.01%	12,404,050	SC 13G/A
Feb 13, 2024	vanguard group inc	9.93%	10,672,076	SC 13G/A
Jan 24, 2024	state street corp	6.35%	6,825,111	SC 13G/A
Jan 23, 2024	blackrock inc.	12.4%	13,303,281	SC 13G/A
Jun 09, 2023	vanguard group inc	10.13%	10,830,433	SC 13G/A
Feb 09, 2023	vanguard group inc	9.70%	10,286,172	SC 13G/A
Feb 08, 2023	state street corp	5.63%	5,970,344	SC 13G/A
Jan 26, 2023	blackrock inc.	12.0%	12,710,631	SC 13G/A
Jan 20, 2023	blackrock inc.	12.0%	12,710,631	SC 13G
Feb 09, 2022	vanguard group inc	9.22%	9,640,143	SC 13G/A

Recent SEC filings of Arrowhead Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 06, 2024	4	Insider Trading
May 02, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 20, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report
Mar 18, 2024	3	Insider Trading

Peers (Alternatives to Arrowhead Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Arrowhead Pharmaceuticals Inc News

Latest updates

Arrowhead Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	16,097,000	15,825,000	146,267,000	62,546,000	31,575,000	32,412,000	151,805,000	27,439,000	38,282,500	45,891,000	32,811,000	21,303,000	7,632,856	27,376,000	23,529,000	29,455,000	43,292,770	42,696,636	48,148,275
Operating Expenses	-9.9%	126,191,000	140,096,000	124,427,000	118,528,000	98,102,000	104,680,000	115,405,000	105,321,000	110,252,000	90,760,000	103,165,000	77,759,000	61,043,000	45,357,000	57,752,000	43,322,000	45,769,000	34,308,000	33,654,778	24,100,887	26,137,583
S&GA Expenses	-100.0%	-	23,605,000	24,572,000	23,771,000	23,221,000	20,985,000	32,028,000	33,141,000	34,267,000	24,995,000	37,399,500	18,434,000	16,346,000	8,802,000	14,267,000	10,749,000	16,326,000	10,934,000	10,268,159	4,809,177	5,338,955
EBITDA Margin	-63.5%	-1.82	-1.12	-0.73	-0.61	-0.48	-0.50	-0.67	-0.57	-0.39	-1.20	-0.96	-1.10	-	-	-	-	-	-	-	-	-
Interest Expenses	35.0%	7,244,000	5,367,000	5,262,000	5,158,000	5,057,000	2,849,000	-	-	-	-	-	-	-	-	-	-	-	-	-437	-	-
Income Taxes	100.0%	-	-3,313,000	2,025,000	742,000	-	17,000	3,785,000	-	-	-	2,000	-	-	-	-	-	-	-	172,800	-	-
Earnings Before Taxes	8.4%	-126,996,000	-138,689,000	-108,990,000	-103,383,000	47,676,000	-41,794,000	-82,157,000	-72,046,000	44,366,000	-62,872,000	-63,372,000	-29,924,000	-26,818,000	-20,732,000	-48,431,000	-13,611,000	-19,836,000	-2,673,000	11,879,057	20,335,708	23,896,982
EBT Margin	-57.6%	-1.99	-1.26	-0.86	-0.70	-0.54	-0.54	-0.71	-0.62	-0.42	-1.27	-1.02	-1.17	-	-	-	-	-	-	-	-	-
Net Income	5.7%	-125,300,000	-132,864,000	-109,679,000	-102,946,000	48,675,000	-41,325,000	-85,511,000	-72,046,000	44,366,000	-62,872,000	-63,374,000	-29,924,000	-26,818,000	-20,732,000	-48,432,715	-13,611,000	-19,836,000	-2,673,000	11,704,906	20,335,708	23,896,982
Net Income Margin	-58.6%	-1.96	-1.23	-0.85	-0.71	-0.55	-0.56	-0.72	-0.62	-0.42	-1.27	-1.02	-1.17	-	-	-	-	-	-	-	-	-
Free Cashflow	32.2%	-126,452,000	-186,496,000	-89,164,000	-68,051,000	-58,985,000	-114,427,000	-101,448,000	-78,351,000	57,977,000	-67,086,000	-32,228,000	-33,541,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	52.5%	955	626	766	796	891	891	692	752	704	639	710	735	757	499	523	556	561	588	350	337	334
Current Assets	127.7%	542	238	420	470	575	575	405	432	418	338	385	526	587	324	322	315	314	508	265	245	235
Cash Equivalents	119.4%	128	58.00	111	105	135	202	108	139	86.00	92.00	184	326	372	140	144	219	257	461	222	188	162
Net PPE	7.8%	359	333	290	231	185	147	110	72.00	55.00	52.00	49.00	48.00	39.00	34.00	31.00	30.00	29.00	26.00	23.00	17.00	13.00
Current Liabilities	2.3%	65.00	64.00	105	70.00	87.00	122	139	128	139	137	147	195	167	25.00	41.00	43.00	53.00	74.00	97.00	87.00	102
Shareholder's Equity	208.8%	495	160	271	365	465	396	418	474	452	373	409	437	446	454	462	493	494	500	244	226	201
Retained Earnings	-10.8%	-1,284	-1,158	-1,026	-916	-813	-862	-820	-735	-663	-707	-644	-581	-551	-524	-503	-455	-441	-421	-419	-431	-451
Additional Paid-In Capital	34.0%	1,769	1,320	1,300	1,281	1,260	1,239	1,219	1,189	1,115	1,080	1,053	1,018	997	979	965	949	936	922	664	657	652
Accumulated Depreciation	-	50.00	-	42.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	15.5%	124	108	107	107	107	106	106	105	105	105	104	104	-	-	-	-	-	-	-	-	-
Minority Interest	-12.7%	12.00	13.00	16.00	17.00	18.00	19.00	20.00	20.00	-	-	-	-	-	-	-	-0.56	-0.56	-0.56	-0.56	-0.56	-0.56
Float	-	-	-	-	-	2,300	-	-	-	4,100	-	-	-	5,900	-	-	-	2,900	-	-	-	1,700

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	21.6%	-92.38	-117	-25.26	-21.45	-31.67	-75.52	-68.74	-68.81	63.00	-61.31	-24.03	-29.61	264	-38.92	-11.26	-33.43	-27.58	-23.53	14.00	11.00	-19.59
Share Based Compensation	-9.9%	18.00	20.00	18.00	20.00	21.00	19.00	29.00	33.00	34.00	25.00	35.00	19.00	15.00	8.00	16.00	10.00	13.00	4.00	5.00	2.00	3.00
Cashflow From Investing	-514.8%	-268	65.00	31.00	-9.90	-36.06	-80.69	36.00	61.00	-69.75	-33.38	-118	-19.54	-34.05	30.00	-65.89	-6.03	-178	9.00	17.00	14.00	-11.22
Cashflow From Financing	161239.7%	431	0.00	0.00	2.00	1.00	251	1.00	61.00	2.00	2.00	1.00	3.00	3.00	5.00	1.00	2.00	1.00	253	2.00	3.00	3.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARWR Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 146,267	$ 3,551	$ 208,813
Operating expenses:
Research and development	101,122	74,881	217,613	158,576
General and administrative	25,069	23,221	48,674	44,206
Total operating expenses	126,191	98,102	266,287	202,782
Operating (loss) income	(126,191)	48,165	(262,736)	6,031
Other income (expense):
Interest income	6,250	4,560	9,052	7,242
Interest expense	(7,244)	(5,057)	(12,611)	(7,906)
Other, net	189	8	610	515
Total other expense	(805)	(489)	(2,949)	(149)
(Loss) income before income tax (benefit) expense and noncontrolling interest	(126,996)	47,676	(265,685)	5,882
Income tax (benefit) expense	0	0	(3,313)	17
Net (loss) income including noncontrolling interest	(126,996)	47,676	(262,372)	5,865
Net loss attributable to noncontrolling interest, net of tax	(1,696)	(999)	(4,208)	(1,485)
Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.	$ (125,300)	$ 48,675	$ (258,164)	$ 7,350
Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:
Basic (in dollars per share)	$ (1.02)	$ 0.46	$ (2.24)	$ 0.07
Diluted (in dollars per share)	$ (1.02)	$ 0.45	$ (2.24)	$ 0.07
Weighted-average shares used in calculating
Basic (in shares)	123,285	106,757	115,307	106,394
Diluted (in shares)	123,285	108,143	115,307	107,893
Other comprehensive (loss) income, net of tax:
Change in unrealized losses on available-for-sale securities	$ 216	$ 0	$ 2,125	$ 0
Foreign currency translation adjustments	(56)	(74)	2	(196)
Comprehensive (loss) income	$ (126,836)	$ 47,602	$ (260,245)	$ 5,669

ARWR Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Sep. 30, 2023
Current assets:
Cash, cash equivalents and restricted cash	$ 127,704	$ 110,891
Available-for-sale securities, at fair value	395,410	292,735
Prepaid expenses	11,022	8,813
Other current assets	7,514	7,082
Total current assets	541,650	419,521
Property, plant and equipment, net	359,252	290,262
Intangible assets, net	9,412	10,262
Right-of-use assets	44,626	45,297
Other assets	210	210
Total Assets	955,150	765,552
Current liabilities:
Accounts payable	8,521	35,866
Accrued expenses	37,055	39,763
Accrued payroll and benefits	13,741	17,963
Lease liabilities	5,285	10,563
Deferred revenue	0	866
Other liabilities	573	435
Total current liabilities	65,175	105,456
Long-term liabilities:
Lease liabilities, net of current portion	113,632	104,608
Liability related to the sale of future royalties	280,938	268,326
Total long-term liabilities	394,570	372,934
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 124,133 and 107,312 shares	217	200
Additional paid-in capital	1,768,866	1,300,395
Accumulated other comprehensive loss	(1,095)	(3,222)
Accumulated deficit	(1,284,194)	(1,026,030)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity	483,794	271,343
Noncontrolling interest	11,611	15,819
Total noncontrolling interest and stockholders’ equity	495,405	287,162
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity	$ 955,150	$ 765,552

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

CEO	Dr. Christopher R. Anzalone Ph.D.
WEBSITE	https://arrowheadpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	397

Arrowhead Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Arrowhead Pharmaceuticals Inc? What does ARWR stand for in stocks?

ARWR is the stock ticker symbol of Arrowhead Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arrowhead Pharmaceuticals Inc (ARWR)?

As of Fri May 17 2024, market cap of Arrowhead Pharmaceuticals Inc is 3.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARWR stock?

You can check ARWR's fair value in chart for subscribers.

What is the fair value of ARWR stock?

You can check ARWR's fair value in chart for subscribers. The fair value of Arrowhead Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arrowhead Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARWR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arrowhead Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ARWR is over valued or under valued. Whether Arrowhead Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Arrowhead Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARWR.

What is Arrowhead Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ARWR's PE ratio (Price to Earnings) is -6.53 and Price to Sales (PS) ratio is 12.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARWR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Arrowhead Pharmaceuticals Inc's stock?

In the past 10 years, Arrowhead Pharmaceuticals Inc has provided 0.082 (multiply by 100 for percentage) rate of return.